Cue Biopharma (CUE) vs Jyong Biotech (MENS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Cue Biopharma (CUE) has outperformed Jyong Biotech (MENS) over the past year, losing 0.4% versus a loss of 96.1%. Cue Biopharma is the larger company by market cap ($200.9 million vs $159.7 million), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CUE | MENS |
|---|---|---|
| Share price | $27.66 | $2.10 |
| Market cap | $200.93M | $159.66M |
| 1-day change | +23.87% | 0.00% |
| YTD return | +202.30% | -46.84% |
| 1-year return | -0.43% | -96.12% |
| 5-year return | -92.68% | — |
| EPS (TTM) | $-29.59 | $-0.06 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $45.50 | $63.00 |
| 52-week low | $4.98 | $1.43 |
| Distance from 52-week high | -39.21% | -96.67% |
| Analyst consensus | strong_buy | — |
| Avg. price target upside | +218.15% | — |
| Average volume | 266.83K | 45.61K |
| Shares outstanding | 7.26M | 74.23M |
| Employees | 29 | 27 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CUE has outperformed MENS by 95.7 percentage points over the past year.
About Cue Biopharma
CUE stock →Cue Biopharma, Inc., a clinical-stage therapeutics company, focuses on developing various therapies for immunological disorders. The company's lead asset is CUE-221, an anti-IgE antibody with a dual-mechanism of action currently in Phase 2 development for allergic diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 29 employees
About Jyong Biotech
MENS stock →Jyong Biotech Ltd., a science-driven biotechnology company, engages in the development and commercialization of plant-derived drugs for the treatment of urinary system diseases in the United States, the European Union, and Asia. It develops Botreso, for the treatment of benign prostate hyperplasia/lower urinary tract symptoms; PCP for treating prostate cancer; and interstitial cystitis (IC) for the treatment of IC/bladder pain syndrome.
Health Care · Biotechnology: Pharmaceutical Preparations · 27 employees
CUE vs MENS FAQ
Which is bigger, Cue Biopharma or Jyong Biotech?
Cue Biopharma (CUE) is larger, with a market capitalization of $200.93M compared with $159.66M for Jyong Biotech (MENS).
Which stock has performed better over the past year, CUE or MENS?
CUE returned -0.43% over the past 12 months, compared with -96.12% for MENS (price return, excluding dividends). Past performance does not predict future results.
Are Cue Biopharma and Jyong Biotech in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.